Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Momo25on Dec 07, 2022 9:29pm
257 Views
Post# 35157968

From Gold to Bronze

From Gold to BronzeNo matters the reasons we invoke and the facts we put in front of their eyes, there will be always some people who are in a denial phase. Share price is at its very low and they are still saying that it is an opportunity for some to buy more. I garantee the share price will hit $0,8 before end of this year, Then maybe it will be an opportunity to inject some money by mid january 2023. At least this is my posture right now. I will buy 30k shares at $0,8 to average at $3 and ignore TH for a while, counting on a legacy drugs to push the share price around $3. Oncology program was a nightmare, NASH is an impossible dream. Paul Levesque and the whole management are just  good to make bronze from gold.
<< Previous
Bullboard Posts
Next >>